Hudziak RM - Search Results

1

Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc.

Hudziak RM, Summerton J, Weller DD, Iversen PL. Hudziak RM, et al. Antisense Nucleic Acid Drug Dev. 2000 Jun;10(3):163-76. doi: 10.1089/oli.1.2000.10.163. Antisense Nucleic Acid Drug Dev. 2000. PMID: 10905553

2

Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation.

Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Hudziak RM, et al. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):267-72. doi: 10.1089/oli.1.1996.6.267. Antisense Nucleic Acid Drug Dev. 1996. PMID: 9012862

3

Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers.

Tai MS, McCartney JE, Adams GP, Jin D, Hudziak RM, Oppermann H, Laminet AA, Bookman MA, Wolf EJ, Liu S, et al. Tai MS, et al. Among authors: hudziak rm. Cancer Res. 1995 Dec 1;55(23 Suppl):5983s-5989s. Cancer Res. 1995. PMID: 7493381

4

Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides.

McCartney JE, Tai MS, Hudziak RM, Adams GP, Weiner LM, Jin D, Stafford WF 3rd, Liu S, Bookman MA, Laminet AA, et al. McCartney JE, et al. Among authors: hudziak rm. Protein Eng. 1995 Mar;8(3):301-14. doi: 10.1093/protein/8.3.301. Protein Eng. 1995. PMID: 7479692

5

Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains.

Dorai H, McCartney JE, Hudziak RM, Tai MS, Laminet AA, Houston LL, Huston JS, Oppermann H. Dorai H, et al. Among authors: hudziak rm. Biotechnology (N Y). 1994 Sep;12(9):890-7. doi: 10.1038/nbt0994-890. Biotechnology (N Y). 1994. PMID: 7765352

6

Tumor targeting in a murine tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2 single-chain Fv.

Huston JS, Adams GP, McCartney JE, Tai MS, Hudziak RM, Oppermann H, Stafford WF 3rd, Liu S, Fand I, Apell G, et al. Huston JS, et al. Among authors: hudziak rm. Cell Biophys. 1994;24-25:267-78. doi: 10.1007/BF02789238. Cell Biophys. 1994. PMID: 7736532

7

Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum.

Hudziak RM, Ullrich A. Hudziak RM, et al. J Biol Chem. 1991 Dec 15;266(35):24109-15. J Biol Chem. 1991. PMID: 1684181 Free article.

8

Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha.

Hudziak RM, Lewis GD, Holmes WE, Ullrich A, Shepard HM. Hudziak RM, et al. Cell Growth Differ. 1990 Mar;1(3):129-34. Cell Growth Differ. 1990. PMID: 2078501

9

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Fendly BM, et al. Among authors: hudziak rm. Cancer Res. 1990 Mar 1;50(5):1550-8. Cancer Res. 1990. PMID: 1689212

10

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. Hudziak RM, et al. Mol Cell Biol. 1989 Mar;9(3):1165-72. doi: 10.1128/mcb.9.3.1165-1172.1989. Mol Cell Biol. 1989. PMID: 2566907 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page